Study Design
Retrospective, propensity score-matched cohort study using the Komodo Healthcare Map US administrative claims database. 11,077 adults with type 2 diabetes or obesity enrolled in Virta's individualized nutrition therapy (VINT) were matched 1:1 to usual-care controls on demographic, clinical and medication covariates (including kidney-protective drugs), with up to 5 years of follow-up. Cox proportional hazards and Poisson regression models.
Intervention
Telehealth-delivered individualized nutrition therapy emphasizing carbohydrate reduction, with remote clinician and health coach support.
Key Results
New-Onset CKD: 36% lower
10.1 vs. 15.6 cases per 1,000 person-years; HR 0.64 (95% CI 0.53-0.77), p<0.001.
CKD Stage 3+: 43% lower
HR 0.57 (95% CI 0.45-0.73), p<0.001.
CKD Stage 4+: 62% lower
HR 0.38 (95% CI 0.18-0.79) — the advanced-CKD endpoint, based on the smallest number of events and therefore the widest confidence interval.
Renal Safety: No increase
No rise in kidney-related adverse events, including kidney stones, metabolic acidosis, diabetic ketoacidosis and gout.
Context & Comparison
Extends the earlier Virta post-hoc analysis in diabetic CKD (262 patients) to a cohort roughly 40 times larger, and moves the endpoint from eGFR slope to hard clinical CKD staging. The population is type 2 diabetes and obesity rather than ADPKD, so it speaks to carbohydrate restriction and kidney protection in general rather than to cyst growth specifically.
Significance
With 22,154 matched adults and up to five years of claims follow-up, this is the largest dataset to date associating a carbohydrate-restricted program with lower incidence and slower progression of chronic kidney disease, and it found no signal of renal harm. Thomas Weimbs — the principal ADPKD ketosis researcher — is a co-author, and the renal safety findings are directly relevant to PKD patients weighing a low-carbohydrate approach. The design is observational and claims-based, so diagnoses come from billing codes rather than lab confirmation.